Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Background: Pembrolizumab is currently the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the association between immune-related adverse events (irAEs) and peripheral blood cell counts remains unclear. We aimed at identifying peripheral blood cell counts t...

Descripción completa

Detalles Bibliográficos
Autores principales: Egami, Saeka, Kawazoe, Hitoshi, Hashimoto, Hironobu, Uozumi, Ryuji, Arami, Toko, Sakiyama, Naomi, Ohe, Yuichiro, Nakada, Hideo, Aomori, Tohru, Ikemura, Shinnosuke, Fukunaga, Koichi, Yamaguchi, Masakazu, Nakamura, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974524/
https://www.ncbi.nlm.nih.gov/pubmed/33754009
http://dx.doi.org/10.7150/jca.53242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974524/
https://www.ncbi.nlm.nih.gov/pubmed/33754009
http://dx.doi.org/10.7150/jca.53242

Ejemplares similares